- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 277/28 - Radicals substituted by nitrogen atoms
Patent holdings for IPC class C07D 277/28
Total number of patents in this class: 428
10-year publication summary
|
30
|
26
|
38
|
25
|
29
|
24
|
29
|
25
|
20
|
9
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Gilead Sciences, Inc. | 2038 |
18 |
| EyePoint Pharmaceuticals, Inc. | 101 |
15 |
| Cyteir Therapeutics, Inc. | 41 |
13 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3162 |
9 |
| Nippon Soda Co., Ltd. | 893 |
8 |
| Shionogi & Co., Ltd. | 851 |
7 |
| Bristol-myers Squibb Company | 4884 |
6 |
| Oryzon Genomics S.A. | 106 |
6 |
| Oncternal Therapeutics, Inc. | 36 |
6 |
| Corteva Agriscience LLC | 2664 |
6 |
| BASF SE | 20915 |
5 |
| Takeda Pharmaceutical Company Limited | 2696 |
5 |
| Intervet Inc. | 909 |
5 |
| The United States Government AS represented by The Department of Veterans Affairs | 1191 |
5 |
| Abbvie Inc. | 1800 |
4 |
| PRAECIS Pharmaceuticals Incorporated | 17 |
4 |
| Toyama Chemical Co., Ltd. | 102 |
4 |
| The University of Toledo | 425 |
4 |
| Calico Life Sciences LLC | 96 |
4 |
| AstraZeneca AB | 2900 |
3 |
| Other owners | 291 |